Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The PATHFINDER Study: A Feasibility Trial (PATHFINDER)

27 de enero de 2021 actualizado por: Balachundhar Subramaniam, Beth Israel Deaconess Medical Center

Perioperative Multimodal General Anesthesia Focusing on Specific CNS Targets in Patients Undergoing Cardiac Surgeries

The main purpose of this study is to determine whether a rational strategy of EEG guided multimodal general anesthesia using target specific sedative and analgesics could result in enhanced recovery after anesthesia and surgery, decrease in postoperative delirium, and decrease in long term postoperative cognitive dysfunction up to 6 months following cardiac surgery.

Descripción general del estudio

Descripción detallada

The main purpose of this study is to determine whether a rational strategy of EEG guided multimodal general anesthesia using target specific sedative and analgesics could result in enhanced recovery after anesthesia and surgery, decrease in postoperative delirium, and decrease in long term postoperative cognitive dysfunction up to 6 months following cardiac surgery.

Specific Aim 1: The feasibility of implementing multimodal general anesthesia strategy in the Operating Rooms (OR) Specific Aim 2: The feasibility of implementing EEG guided sedation until extubation in the Intensive Care Unit (ICU) Specific Aim 3: The enhancement of recovery after surgery (shorter ventilation time, ICU stay, hospital length of stay) Specific Aim 4: To estimate the effect size of decrease in postoperative day (POD) and postoperative cognitive dysfunction (POCD) to power future large randomized trials

Tipo de estudio

Intervencionista

Inscripción (Actual)

22

Fase

  • Fase temprana 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Beth Israel Deaconess Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

60 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Age ≥ 60 years
  2. Undergoing any of the following types of surgery with cardiopulmonary bypass limited to coronary artery bypass surgery (CABG), CABG+valve surgeries and isolated valve surgeries.

Exclusion Criteria:

  1. Preoperative left ventricular ejection fraction (LVEF) <30%
  2. Emergent surgery
  3. Non-English speaking
  4. Cognitive impairment as defined by total MoCA score < 10
  5. Currently enrolled in another interventional study that could impact the primary outcome, as determined by the PI
  6. Significant visual impairment
  7. Chronic opioid use for chronic pain conditions with tolerance (total dose of an opioid at or more than 30 mg morphine equivalent for more than one month within the past year)
  8. Hypersensitivity to any of the study medications
  9. Known history of alcohol (> 2 drinks per day) or drug abuse Active (in the past year) history of alcohol abuse (≥5 drinks/day for men or ≥4 drinks/day for women) as determined by reviewing medical record and history given by the patient
  10. Liver dysfunction (liver enzymes > 4 times the baseline, all patients will have a baseline liver function test evaluation), history and examination suggestive of jaundice.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Multimodal General Anesthesia

Intraoperative

The anesthesiologists involved in this study will be trained to infer differences in anti-nociception, unconsciousness movement and changes during other perioperative events by monitoring EEG. They will also be trained in titrating hypnotic and nociceptic medications based on changes in EEG.

  1. Routine anesthetic induction
  2. Bilateral Pectoro-interfascial block (PIFB) with 20 mL of 0.25% ropivacaine on either side of the sternum after anesthetic induction but before surgical incision
  3. Ketamine (0.06 to 0.12 mg.kg/hr)
  4. Remifentanil (0.05-0.2 mcg/kg/min)
  5. Dexmedetomidine (0.2-1.0 mcg/kg/hr)
  6. Rocuronium intermittent bolus (TOF)
  7. Propofol infusion ± Sevoflurane titrated based on EEG monitoring

Postoperative

  1. Standard pain management protocol
  2. Dexmedetomidine infusion 0.2-1.4 mcg/kg/hr (EEG guided)
  3. Infusion continued till extubation
  4. Propofol infusion may be added/used for sedation based on the treating physician's discretion
Infusión intraoperatoria
Infusión intraoperatoria
Infusión intraoperatoria
Bolo intermitente intraoperatorio
Infusión intraoperatoria
Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
Intraoperative inhaled as needed
Post-operative infusion
Post-operative infusion
Perioperative monitoring
Otro: Standard Practice with EEG monitoring
The initial 2 patients will receive standard anesthesia practice and perioperative EEG monitoring will be recorded to learn the patterns associated with our standard practice.
Perioperative monitoring

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of Delirium
Periodo de tiempo: Participants will be followed for the duration of the hospital stay, an average of 5 days
Incidence of delirium will be analyzed in patients treated with the multi-modal approach. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM)Assessment Method (CAM) algorithm postoperatively until discharge.
Participants will be followed for the duration of the hospital stay, an average of 5 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to extubation
Periodo de tiempo: Time of ICU admission until time of extubation in ICU, an average of 6 hours
Time to extubation will be noted from ICU data
Time of ICU admission until time of extubation in ICU, an average of 6 hours
Montreal Cognitive Assessment (MoCA)
Periodo de tiempo: On the day of discharge, an average of 6 days
MoCA scores (total possible score is 30 points; a score of 26 or above is considered normal) at discharge will be reported in order to assess the occurrence of postoperative cognitive decline. Study staff trained in administering the assessments will collect the data.
On the day of discharge, an average of 6 days
Pain scores
Periodo de tiempo: At 4-8 hourly intervals every day until discharge, an average of 6 days
Patient reported pain scores on a scale from 0-10 (0 no pain,10 extreme pain), until discharge for the index admission.
At 4-8 hourly intervals every day until discharge, an average of 6 days
Total opioid and supplemental analgesic consumption
Periodo de tiempo: 48 hours, post-operative
The total opioid dosage and supplemental analgesic dosage received in the first 48 hours postoperatively will be abstracted from the medical record.
48 hours, post-operative
ICU
Periodo de tiempo: Time of ICU admission until time of discharge to hospital floor; through the hospital stay, an average of 5 days
Total duration of stay in ICU for the index admission
Time of ICU admission until time of discharge to hospital floor; through the hospital stay, an average of 5 days
ICU/hospital length of stay
Periodo de tiempo: Time of stay in the hospital until discharge to floor or rehab, an average of 5 days
Their stay in the hospital for the index admission
Time of stay in the hospital until discharge to floor or rehab, an average of 5 days
In-hospital complications
Periodo de tiempo: 7 days post-op on an average
stroke, myocardial infarction (MI), acute kidney injury, pneumonia, reintubation, congestive heart failure, sepsis, reopening of sternum and all-cause mortality
7 days post-op on an average
Follow up incidence of delirium
Periodo de tiempo: Patients will be assessed for delirium at 1 month and 6 months following the date of surgery
The follow up incidence of delirium will be analyzed at 1 month and 6 months after discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the MoCA/t-MoCA.
Patients will be assessed for delirium at 1 month and 6 months following the date of surgery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de agosto de 2019

Finalización primaria (Actual)

19 de febrero de 2020

Finalización del estudio (Actual)

7 de julio de 2020

Fechas de registro del estudio

Enviado por primera vez

9 de julio de 2019

Primero enviado que cumplió con los criterios de control de calidad

10 de julio de 2019

Publicado por primera vez (Actual)

11 de julio de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de enero de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

27 de enero de 2021

Última verificación

1 de enero de 2021

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Ketamina

3
Suscribir